Evidence map›Paper›PMID 40295006›Full record

ArticleIn vivo (Athens, Greece)

Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.

Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Takafumi Yanagisawa, Wataru Fukuokaya, Ryoichi Maenosono, Yuki Yoshikawa, Takuya Tsujino, Masanobu Saruta and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mamoru HashimotoDepartment of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
Ken FukiageDepartment of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
Kosei TaniguchiDepartment of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
Takafumi MinamiDepartment of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
Takafumi YanagisawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Wataru FukuokayaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Ryoichi MaenosonoDepartment of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yuki YoshikawaDepartment of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Takuya TsujinoDepartment of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Masanobu SarutaDepartment of Urology, Fujita-Health University School of Medicine, Aichi, Japan.
Kiyoshi TakaharaDepartment of Urology, Fujita-Health University School of Medicine, Aichi, Japan.
Yosuke HirasawaDepartment of Urology, Tokyo Medical University, Tokyo, Japan.
Takeshi HashimotoDepartment of Urology, Tokyo Medical University, Tokyo, Japan.
Yoshio OhnoDepartment of Urology, Tokyo Medical University, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Ryoichi ShirokiDepartment of Urology, Fujita-Health University School of Medicine, Aichi, Japan.
Kazutoshi Fujita
ULTRA-J group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCancer-induced pain (CIP) exacerbates patient's quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV-treated UC patients. PATIENTS AND

methodsWe analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer-related pain or the use of analgesics for pain management.

resultsA total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression-free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS.

conclusionCIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.

Indexed as

Antibodies, MonoclonalCancer PainAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisQuality of LifeRetrospective StudiesTreatment OutcomeAntibodies, Monoclonalenfortumab vedotinCancer-induced painEnfortumab Vedotinurothelial carcinoma

Identifiers

PMID40295006
PMCPMC12041981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.